Gary R. Lichtenstein

Update: ACG Guidelines for the Treatment of Crohn’s Disease

12/14/2019

Extraintestinal Manifestations at Baseline, and Effect of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis in the OCTAVE Program

BACKGROUND: Extraintestinal manifestations (EIMs) occur in approximately one-third of patients with ulcerative colitis (UC) (1). Tofacitinib is an oral, small molecule JAK inhibitor for t...

Paulo Gustavo Kotze ;

David T. Rubin , MD;

Marcia Pinheiro ;

Gary R. Lichtenstein ;

Haiyun Fan ;

Walter Reinisch ;

Marc Fellmann ;

Irene Modesto ;

Nervin Lawendy ;

Eric Maller ;

Thomas Greuter ;

Stephen Vavricka ;

12/12/2019

Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn’s Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials

1 Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States; 2 Cleveland Clinic, Cleveland, Ohio, United States; 3 Icahn School of Medicine at Mount Sinai, New York...

Bruce E. Sands , MD, MS;

Loftus Edward ;

Fernando Margo ;

Peter Lakatos ;

Ana Lacerda ;

Brooke Kim ;

John Liu ;

Samuel Anyanwu ;

Kristina Kligys ;

Andrew Garrison ;

Gary R. Lichtenstein ;

Tim Raine ;